RIGL FY 2017 Earnings — Rigel Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RIGLRigel Pharmaceuticals, Inc.

$517M

FY 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M-78.0% YoY

Gross Profit

-$42M-931.9% margin

Operating Income

-$80M-1775.6% margin

Net Income

-$78M-1739.3% margin

EPS (Diluted)

$-6.17

Cash Flow

Operating Cash Flow

-$78M

Free Cash Flow

-$78M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$119M

Total Liabilities

$18M

Stockholders' Equity

$101M

Cash & Equivalents

$38M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$20M	-78.0%
Gross Profit	-$42M	-$43M	+3.0%
Operating Income	-$80M	-$70M	-14.2%
Net Income	-$78M	-$69M	-12.7%